Elanco Animal Health Inc.
- ELAN · NYSE
- Pharmaceutical Preparations
- Indianapolis, IN
- 1,000 employees
- CIK 0001739104
Updated from SEC filings through
Top things to know
Revenue, FY2025$4.7B+6.2% vs FY2024Employees1,000As of December 31, 2025
Next earningsNovember 6, 202608:30:00 America/New_York
Latest 8-KResults of operations and financial conditionFiled November 6, 2026 Executives
-
Jeffrey N. Simmons PRESIDENT, CEO AND DIRECTOR 4, 2026-09-22 - Robert M. VanHimbergen EVP and CFO 4, 2026-09-22
- Bob VanHimbergen Executive Vice President and CFO of Elanco Animal Health 8-K, 2026-08-05
- Robert VanHimbergen Executive Vice President and Chief Financial Officer DEF 14A, 2026-04-08
- Jamie Preston EVP, Chief People Officer 3, 2026-11-03
- James M. Meer CHIEF ACCOUNTING OFFICER 4, 2026-03-05
What leadership is saying
“Elanco achieved significant adjusted gross margin expansion in the third quarter, up 300 basis points reflecting accelerating price gains to 4% year-over-year and beneficial mix, as well as early progress on our Elanco Ascend productivity initiatives”
Earnings press release (8-K Ex. 99.1), filed November 6, 2026
Elanco Animal Health Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Indianapolis, IN. It trades as ELAN on NYSE. Revenue was $4.7B in the fiscal year ending December 31, 2025, +6.2% from the year before. It reported about 1,000 employees. Jeffrey N. Simmons is PRESIDENT, CEO AND DIRECTOR.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.7B 10-K, 2026-02-24 | $4.4B 10-K, 2026-02-24 | $4.4B 10-K, 2026-02-24 | $4.4B 10-K, 2025-02-25 | $4.8B 10-K, 2024-02-26 |
| Operating income | Not on file | Not on file | Not on file | Not on file | Not on file |
| SG&A | $1.4B 10-K, 2026-02-24 | $1.3B 10-K, 2026-02-24 | $1.3B 10-K, 2026-02-24 | $1.3B 10-K, 2025-02-25 | $1.4B 10-K, 2024-02-26 |
| Net income | -$232M 10-K, 2026-02-24 | $338M 10-K, 2026-02-24 | -$1.2B 10-K, 2026-02-24 | -$78.0M 10-K, 2025-02-25 | -$483M 10-K, 2024-02-26 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Jeffrey N. Simmons President & CEO at Elanco | Passionate about people, growth & leadership | Advancing animal care to fuel the protein revolution & meet pet owner expectations | | PRESIDENT, CEO AND DIRECTOR | 4, 2026-09-22 |
| Robert M. VanHimbergen Executive Vice President and Chief Financial Officer at Elanco | EVP and CFO | 4, 2026-09-22 |
| Bob VanHimbergen | Executive Vice President and CFO of Elanco Animal Health | 8-K, 2026-08-05 |
| Robert VanHimbergen | Executive Vice President and Chief Financial Officer | DEF 14A, 2026-04-08 |
| Jamie Preston | EVP, Chief People Officer | 3, 2026-11-03 |
 Rajeev (Bobby) Modi | Named in proxy bio: Executive Vice President, U.S. Pet Health and Global Digital Transformation | DEF 14A, 2026-04-08 |
| David Kinard | Named in proxy bio: Executive Vice President, Human Resources, Corporate Communications and Administration | DEF 14A, 2026-04-08 |
| James Meer | Named in proxy bio: Senior Vice President, Chief Accounting Officer | DEF 14A, 2026-04-08 |
| José Manuel Correia de Simas, Ph.D. | Named in proxy bio: Executive Vice President, U.S. Farm Animal Business | DEF 14A, 2026-04-08 |
| James M. Meer | CHIEF ACCOUNTING OFFICER | 4, 2026-03-05 |
 Shiv O'Neill | GC AND CORP SEC | 4, 2026-08-18 |
 Grace McArdle Executive Vice President Manufacturing and Quality at Elanco | EVP, MANUFACTURING AND QUALITY | 4, 2026-03-05 |
| Art Garcia | Board member (per proxy) bio: Director Nominee | DEF 14A, 2026-04-08 |
| Kapila Anand | Board member (per proxy) bio: Director Nominee | DEF 14A, 2026-04-08 |
| Michael Harrington | Board member (per proxy) bio: Director Nominee | DEF 14A, 2026-04-08 |
| Lawrence E. Kurzius | Chairman of the Board | 10-K, 2026-02-24 |
What Elanco Animal Health Inc does
Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 499.8 million (as of November 4, 2026) | 10-Q, November 6, 2026 |
|---|---|---|
| Public float | $7.0B (as of June 30, 2025) | 10-K, February 24, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 6, 2026 |
| Latest proxy statement | Meeting December 31, 2025 (filed April 8, 2026) | DEF 14A, April 8, 2026 |
| Auditor | Ernst & Young LLP (Indianapolis, Indiana) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| October 15, 2026 | Timothy J. Bettington SEE REMARKS | Sale | 4,350 | $100K | Form 4, October 19, 2026 |
| August 20, 2026 | Lawrence Erik Kurzius Director | Buy | 40,000 | $936K | Form 4, August 21, 2026 |
| August 18, 2026 | Shiv O'Neill GC AND CORP SEC | Buy | 3,998 | $94K | Form 4, August 18, 2026 |
| August 12, 2026 | Michael J. Harrington Director | Buy | 5,000 | $109K | Form 4, August 13, 2026 |
| August 7, 2026 | Robert M. VanHimbergen EVP and CFO | Buy | 4,200 | $97K | Form 4, August 10, 2026 |
| August 7, 2026 | Paul Herendeen Director | Buy | 10,000 | $237K | Form 4, August 10, 2026 |
| May 15, 2026 | Rajeev A. Modi SEE REMARKS | Buy | 4,911 | $100K | Form 4, May 19, 2026 |
| May 15, 2026 | Jeffrey N. Simmons PRESIDENT, CEO AND DIRECTOR | Buy | 4,971 | $100K | Form 4, May 19, 2026 |
Recent 8-K events
- 8-K filed 2026-11-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-27
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-02-24
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-12
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-12-09
- Item 2.05 Costs associated with exit or disposal activities (restructuring)
- Item 7.01 Regulation FD disclosure
- 8-K filed 2025-11-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-03
- Item 1.01 Entry into a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- 8-K filed 2025-08-07
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Elanco Animal Health Inc
- What does Elanco Animal Health Inc do?
- In its own words, from Item 1 of its 10-K: "Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve."
- What is Elanco Animal Health Inc's revenue?
- $4.7B for the fiscal year ending December 31, 2025, from its 10-K filed February 24, 2026.
- Is Elanco Animal Health Inc profitable?
- Elanco Animal Health Inc reported net income of -$232M for the fiscal year ending December 31, 2025.
- How many employees does Elanco Animal Health Inc have?
- About 1,000 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Elanco Animal Health Inc?
- Jeffrey N. Simmons, PRESIDENT, CEO AND DIRECTOR, as named in a 4 filed September 22, 2026.
- Who is the CFO of Elanco Animal Health Inc?
- Robert M. VanHimbergen, EVP and CFO, as named in a 4 filed September 22, 2026.
- Where is Elanco Animal Health Inc headquartered?
- Indianapolis, IN.
- What is Elanco Animal Health Inc's stock ticker?
- ELAN on NYSE.
- What industry is Elanco Animal Health Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Elanco Animal Health Inc's website?
- elanco.com.
- When does Elanco Animal Health Inc report earnings next?
- November 6, 2026 at 08:30:00. Source: ir_event.
- Is Elanco Animal Health Inc a public company?
- Yes. Elanco Animal Health Inc files with the SEC under CIK 0001739104 and trades as ELAN.
- Who audits Elanco Animal Health Inc?
- Ernst & Young LLP, Indianapolis, Indiana, as named in its latest annual report (10-K).
- How many shares of Elanco Animal Health Inc are outstanding?
- 499.8 million shares as of November 4, 2026, from its 10-Q filed November 6, 2026.
- What is Elanco Animal Health Inc's public float?
- $7.0B as of June 30, 2025, as reported on the cover of its 10-K filed February 24, 2026.
- How many business segments does Elanco Animal Health Inc report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 6, 2026.
- When is Elanco Animal Health Inc's annual shareholder meeting?
- December 31, 2025, per its proxy statement (DEF 14A) filed April 8, 2026.
- Have Elanco Animal Health Inc insiders traded stock recently?
- Since December 11, 2025, officers and directors reported 1 open-market sale worth about $100K and 11 purchases worth about $2.6M on Forms 4 and 5. The most recent: Timothy J. Bettington (SEE REMARKS) sold 4,350 shares on October 15, 2026.